Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and
efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).